Insulet Co. (NASDAQ:PODD) Shares Sold by Blair William & Co. IL

Blair William & Co. IL lowered its position in Insulet Co. (NASDAQ:PODD) by 2.5% during the fourth quarter, HoldingsChannel.com reports. The fund owned 183,285 shares of the medical instruments supplier’s stock after selling 4,778 shares during the quarter. Blair William & Co. IL’s holdings in Insulet were worth $47,850,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of PODD. Baillie Gifford & Co. increased its holdings in Insulet by 3.5% during the 4th quarter. Baillie Gifford & Co. now owns 2,355,683 shares of the medical instruments supplier’s stock valued at $614,998,000 after acquiring an additional 79,982 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Insulet by 1.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,738,601 shares of the medical instruments supplier’s stock worth $403,339,000 after purchasing an additional 22,850 shares in the last quarter. Artisan Partners Limited Partnership raised its position in shares of Insulet by 24.1% during the 4th quarter. Artisan Partners Limited Partnership now owns 770,188 shares of the medical instruments supplier’s stock worth $201,073,000 after purchasing an additional 149,524 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Insulet by 1.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 646,959 shares of the medical instruments supplier’s stock valued at $168,902,000 after buying an additional 10,694 shares in the last quarter. Finally, Fisher Asset Management LLC lifted its stake in Insulet by 7.6% in the 4th quarter. Fisher Asset Management LLC now owns 377,694 shares of the medical instruments supplier’s stock valued at $98,605,000 after buying an additional 26,594 shares in the last quarter.

Insulet Price Performance

PODD stock opened at $260.27 on Friday. The company has a market cap of $18.28 billion, a PE ratio of 44.95, a price-to-earnings-growth ratio of 3.62 and a beta of 1.29. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. The stock has a 50-day moving average price of $272.03 and a two-hundred day moving average price of $258.25. Insulet Co. has a 12-month low of $160.19 and a 12-month high of $289.46.

Insulet (NASDAQ:PODD) last issued its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.00 by $0.15. The business had revenue of $597.50 million during the quarter, compared to analysts’ expectations of $582.02 million. Insulet had a return on equity of 24.46% and a net margin of 20.19%. As a group, research analysts predict that Insulet Co. will post 3.92 EPS for the current year.

Insiders Place Their Bets

In other Insulet news, Director Wayne A.I. Frederick sold 1,825 shares of the firm’s stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total value of $501,875.00. Following the transaction, the director now directly owns 3,231 shares of the company’s stock, valued at $888,525. This trade represents a 36.10 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Eric Benjamin sold 12,394 shares of the company’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the sale, the executive vice president now directly owns 11,383 shares of the company’s stock, valued at $3,187,240. The trade was a 52.13 % decrease in their position. The disclosure for this sale can be found here. 0.47% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

PODD has been the subject of several recent research reports. Stifel Nicolaus boosted their price target on Insulet from $245.00 to $293.00 and gave the stock a “hold” rating in a report on Friday, February 21st. StockNews.com downgraded shares of Insulet from a “buy” rating to a “hold” rating in a research note on Tuesday, March 4th. JPMorgan Chase & Co. upped their target price on shares of Insulet from $280.00 to $330.00 and gave the company an “overweight” rating in a report on Thursday, December 12th. TD Cowen lifted their price target on shares of Insulet from $264.00 to $324.00 and gave the stock a “buy” rating in a report on Friday, January 3rd. Finally, Canaccord Genuity Group upped their price objective on shares of Insulet from $304.00 to $324.00 and gave the company a “buy” rating in a research note on Friday, February 21st. Four research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $292.06.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.